ArticleAnnals of surgical oncology2023
ASO Author Reflections: NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Resectable, High-Risk Intrahepatic Cholangiocarcinoma.
Shishir K MaithelPubMed ↗Publisher ↗
No numbers read from the abstract.